Composition: Nifedipine IP 10 mg (uncoated); Nifin-10 Nifedipine BP 10 mg (uncoated); Nifin-20 Nifedipine BP 20 mg (uncoated); Nifelace-20 Nifedipine BP 20 mg (film-coated slow-release).
Dosage forms: Immediate-release uncoated tablets (10 mg / 20 mg); separate slow-release variant (20 mg).
Usage: Cardiovascular treatment only under an approved prescription; suitability depends on release formulation.
Category: Anti Cardiovascular Drugs
Therapeutic category: Dihydropyridine calcium-channel blocker / antianginal / antihypertensive
Brands: Nifin-10, Nifin-20, Nifelace-20 (slow release)
SKU: Nifedipine Tablets
Categories: Pharmaceutical Exporter India, Pharmaceutical Formulations India, WHO GMP Certified Formulations
Nifedipine Tablets Trader is listed in our pharmaceutical product portfolio for business-to-business enquiries. Product-specific formulation details, available strengths, dosage form, pack configuration and supply terms should be confirmed against the current product specification before ordering.
For distributor, wholesaler, hospital procurement and export enquiries, please request the applicable product specifications, batch documentation, shelf-life information, packaging options and regulatory documents. Availability and documentation depend on the product and destination market.
Manufacturer: Healthy Life Pharma Pvt. Ltd. (certification subject to verification). Exporter: Healthy Inc (export credentials subject to verification).
Nifedipine is a dihydropyridine calcium-channel blocker that relaxes arterial smooth muscle. The supplied catalog includes uncoated nifedipine tablets and a separately identified film-coated slow-release brand. These dosage forms must not be treated as interchangeable: release characteristics affect clinical use, dosing and safety. Product selection should follow the locally approved label and prescriber's assessment.
| Variant | Composition per tablet | Dosage form | Standard as supplied |
|---|---|---|---|
| Nifedipine Tablets | Nifedipine 10 mg; excipients q.s. | Uncoated, immediate release | IP |
| Nifin-10 | Nifedipine 10 mg | Uncoated, immediate release | BP |
| Nifin-20 | Nifedipine 20 mg | Uncoated; release profile to confirm on label | BP |
| Nifelace-20 | Nifedipine 20 mg | Film-coated slow release | BP |
CAS: 21829-25-4. Class: Calcium-channel blocker. Packaging, shelf life and finished-product approvals: Verify against the applicable product documentation. The 5 mg strength in the marketing description is not supported by the supplied compositions.
Nifedipine is light-sensitive. Suitable light-protective processing, packaging and validated stability controls are important. Immediate-release and slow-release tablets require distinct formulation development and release testing. Specific claims regarding sodium-vapor lighting, coatings, milling or proprietary processing require manufacturer confirmation.
Appropriate finished-product controls may include identification, assay, impurities, content uniformity, disintegration or dissolution, and stability. Slow-release tablets additionally require a validated multi-time-point dissolution profile. Acceptance criteria depend on the applicable monograph and approved specifications; numerical limits should not be asserted without records.
Nifedipine inhibits L-type calcium channels, relaxing vascular smooth muscle and reducing arterial resistance. Depending on the exact formulation and local authorization, nifedipine may be prescribed for selected angina and blood-pressure indications. Immediate-release nifedipine should not be used for rapid unsupervised reduction of high blood pressure or sublingually for hypertensive emergencies, because abrupt hypotension and ischemic complications may occur. Off-label uses, including selected obstetric applications, require specialist oversight.
Pharmacopoeial status, marketing authorization, manufacturer licensing, country-specific import requirements, and availability of COA, COPP, FSC or CTD/ACTD dossiers must be confirmed for each market. WHO-GMP and Star Export House designations are not independently verified here.
Are Nifin-20 and Nifelace-20 the same? No. The supplied Nifin-20 is an uncoated 20 mg tablet, whereas Nifelace-20 is explicitly slow release. Do not substitute one for the other without professional review.
Can nifedipine tablets be used under the tongue for a sudden BP rise? No; immediate-release or sublingual use for hypertensive emergencies is discouraged because blood pressure may fall unpredictably.
Is grapefruit juice suitable? Grapefruit can increase nifedipine exposure; patients should follow their prescriber's advice and product labeling.
Dosage, frequency and treatment duration depend on indication, patient condition, release formulation and approved prescribing information. Do not assume that an immediate-release schedule applies to Nifelace-20. Slow-release tablets should not be crushed or chewed; splitting is appropriate only if the product label expressly permits it.
Potential effects include headache, flushing, dizziness, hypotension, palpitations or reflex tachycardia, and peripheral edema. Gingival enlargement may occur with prolonged use. Clinicians should assess cardiac status, other antihypertensive medicines, CYP3A4 interactions and pregnancy-related considerations. Seek urgent care for fainting, severe chest pain or other serious symptoms.
Protect from light and moisture, retain in the original packaging, and follow the temperature and storage conditions printed on the approved product label. Keep out of children's reach.
Information for product identification and healthcare-professional reference only; not individualized medical advice. Formulations, certifications and availability require verification before publication or purchase.